Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 5 Results

Title
Intervention Indication Therapeutic Area Year Actions
Filgotinib for moderate to severe active rheumatoid arthritis Filgotinib (GLPG-0634; filgotinib maleate) , Methotrexate (MTX; Otrexup; Vibex MTX; MQX-5902; methotrexate disodium; methotrexate sodium) , other nonbiologic DMARDs Rheumatoid arthritis Rheumatology 2019 View  |  Download
Otilimab in combination with conventional synthetic DMARDs for treating rheumatoid arthritis Otilimab Rheumatoid arthritis Rheumatology 2022 View  |  Download
Tocilizumab (RoACTEMRA) [subcutaneous injection with an auto injector device] for adult patients with moderate to severe active rheumatoid arthritis - after DMARD failure Tocilizumab (Actemra; R1569; RoActemra) Rheumatoid arthritis Rheumatology 2017 View  |  Download
Tocilizumab biosimilar for treating moderate to severe active rheumatoid arthritis Tocilizumab biosimilar (Avtozma) Rheumatoid arthritis Rheumatology 2023 View  |  Download
Upadacitinib for Adults with Moderate to Severe Active Rheumatoid Arthritis After Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs) or Biologic DMARDs Failure Upadacitinib (ABT-494; Rinvoq; upadacitinib hemihydrate) Rheumatoid arthritis Rheumatology 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications